Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
- PMID: 15479682
- PMCID: PMC1774300
- DOI: 10.1136/gut.2003.037747
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
Abstract
Background and aims: Evidence exists for the pathogenic role of the enteric flora in inflammatory bowel disease. Probiotics contain living microorganisms which exert health effects on the host. We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis.
Patients and methods: In total, 327 patients were recruited and assigned to a double blind, double dummy trial to receive either the probiotic drug 200 mg once daily (n = 162) or mesalazine 500 mg three times daily (n = 165). The study lasted for 12 months and patients were assessed by clinical and endoscopic activity indices (Rachmilewitz) as well as by histology. The primary aim of the study was to confirm equivalent efficacy of the two drugs in the prevention of relapses.
Results: The per protocol analysis revealed relapses in 40/110 (36.4%) patients in the E coli Nissle 1917 group and 38/112 (33.9%) in the mesalazine group (significant equivalence p = 0.003). Subgroup analyses showed no differences between the treatment groups in terms of duration and localisation of disease or pretrial treatment. Safety profile and tolerability were very good for both groups and were not different.
Conclusions: The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis. The effectiveness of probiotic treatment further underlines the pathogenetic significance of the enteric flora.
Figures




Similar articles
-
[Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].Z Gastroenterol. 2006 Mar;44(3):267-9. doi: 10.1055/s-2005-858972. Z Gastroenterol. 2006. PMID: 16514573 German. No abstract available.
-
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.Lancet. 1999 Aug 21;354(9179):635-9. doi: 10.1016/s0140-6736(98)06343-0. Lancet. 1999. PMID: 10466665 Clinical Trial.
-
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.Aliment Pharmacol Ther. 1997 Oct;11(5):853-8. doi: 10.1046/j.1365-2036.1997.00225.x. Aliment Pharmacol Ther. 1997. PMID: 9354192 Clinical Trial.
-
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.World J Gastroenterol. 2016 Jun 28;22(24):5505-11. doi: 10.3748/wjg.v22.i24.5505. World J Gastroenterol. 2016. PMID: 27350728 Free PMC article. Review.
-
Probiotics for maintaining remission of ulcerative colitis in adults.Ann Pharmacother. 2010 Mar;44(3):565-71. doi: 10.1345/aph.1M498. Epub 2010 Feb 2. Ann Pharmacother. 2010. PMID: 20124461 Review.
Cited by
-
Experimental administration of the probiotic Escherichia coli strain Nissle 1917 results in decreased diversity of E. coli strains in pigs.Curr Microbiol. 2012 Mar;64(3):205-10. doi: 10.1007/s00284-011-0051-x. Epub 2011 Nov 25. Curr Microbiol. 2012. PMID: 22116501 Clinical Trial.
-
A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome.Int J Colorectal Dis. 2012 Apr;27(4):467-74. doi: 10.1007/s00384-011-1363-9. Epub 2011 Dec 2. Int J Colorectal Dis. 2012. PMID: 22130826 Free PMC article. Clinical Trial.
-
Dextran sodium sulfate-induced inflammation alters the expression of proteins by intestinal Escherichia coli strains in a gnotobiotic mouse model.Appl Environ Microbiol. 2012 Mar;78(5):1513-22. doi: 10.1128/AEM.07340-11. Epub 2011 Dec 30. Appl Environ Microbiol. 2012. PMID: 22210207 Free PMC article.
-
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin.Infect Immun. 2007 May;75(5):2399-407. doi: 10.1128/IAI.01563-06. Epub 2007 Feb 5. Infect Immun. 2007. PMID: 17283097 Free PMC article.
-
The "Cins" of Our Fathers: Rejuvenated Interest in Colicins to Combat Drug Resistance.J Microbiol. 2023 Feb;61(2):145-158. doi: 10.1007/s12275-023-00023-x. Epub 2023 Feb 8. J Microbiol. 2023. PMID: 36753040 Review.
References
-
- British Society of Gastroenterology. Clinical practice guidelines: inflammatory bowel disease. 1996. www.bsg.org.uk/clinical-prac/guidelines.htm.
-
- Stange EF, Riemann J, von Herbay A, et al. Diagnosis and therapy of ulcerative colitis—results of an evidence-based consensus conference of the German Society of Digestive and Metabolic Diseases. Z Gastroenterol 2001;39:19–20. - PubMed
-
- Travis SP, Jewell DP. Salicylates for ulcerative colitis—their mode of action. Pharmacol Ther 1994;63:135–61. - PubMed
-
- Shanahan F . Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000;6:107–15. - PubMed
-
- D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical